F
or decades, constructive collaborations between investigators and industry have benefi ted patients and the public. Recently, high-profi le lawsuits (1) , public interest groups, and politicians (2) have raised concerns that fi nancial and other interests may unduly infl uence professional judgment and threaten the integrity of scientifi c research.
As a result of the attention regarding payments to physicians, a sense of urgency has arisen to better detect and deal with confl icts. Multiple eff orts have emerged to mitigate the confl icts and promote objectivity in research. Individual states (3), professional organizations (4) , and even industry (5) promote more rigorous reporting and restrictions. In addition to the Food and Drug Administration (FDA) regulations (6), the Public Health Service (PHS) National Institutes of Health (NIH) proposed new, more stringent guidelines in May 2010 aimed at preventing fi nancial confl ict of interests among researchers who receive federal research funding (7) .
Starting September 30, 2013, the Physician Payment Sunshine Act (8) , a provision of the Patient Protection and Aff ordable Care Act, will require manufacturers of drugs, devices, biologicals, and medical supplies to post payments or other transfers of value over $10 (or lesser-value items when the aggregated amount exceeds $100 during the calendar year to a single provider) that are made to physicians. Th is applies to payments made for research funding and grants. Th e information will be posted on a public website that is searchable and in a format that is easy to understand.
Th e goal of these regulations and the internal policies implemented by institutions (including Baylor Health Care System) is to protect research participants, maintain the integrity of professional judgment and science, and preserve trust in research. When bias occurs in research, there is the potential of harm to participants, damage to the reputations of researchers and institutions, and possible distrust of the research fi ndings. Well-formulated institutional policies for addressing confl icts can assist the institution in mitigating bias by identifying potential confl ict of interests and prospectively determining whether the confl icting relationships should be allowed, managed, or eliminated.
WHAT IS A CONFLICT OF INTEREST IN RESEARCH?
Confl icts arise when a researcher's personal interests have the potential to compromise the researcher's professional judgment and independence in the design, conduct, or publication of research. Almost anything with the potential to aff ect judgment presents a concern and is considered a confl ict. Simply the perception that a confl ict may exist creates the need for review of the interest.
While many varieties of confl icts exist, spanning a wide range of circumstances, it is important to note that confl ict of interest is not research misconduct. Research misconduct involves fabrication, falsifi cation, or plagiarism in proposing, performing, or reviewing research or in reporting research results (9). A confl ict of interest involves the potential use of personal authority for private gain. It may be possible for a confl ict to result in misconduct, or misconduct may have at its basis a confl ict, but confl icts do not automatically equal research misconduct.
Financial interests are the most obvious type of confl ict and often the easiest to identify. Researchers may have an array of fi nancial ties to drug, device, and biotech companies. Researchers are commonly compensated for a wide range of activities including consulting, speaking, instructing, and serving on advisory boards. Compensation includes gifts, research equipment, computers, trips, and discretionary funds from industry. Researchers may also own intellectual property, potentially resulting in licensing and royalty fees. Serving on a company's board of directors or as an offi cer of the company presents confl icts that may be fi nancial or motivated by other factors. Regardless of the monetary amount involved, all these situations present the potential for confl ict.
Financial confl icts are not the only type of confl ict present in the research setting. Th e desire for notoriety, publications, media attention, increased patient referrals, job security, promotion, tenure, and the ability to secure government grants and future research funding of research projects may all present opportunity for confl icts and potential research misconduct.
Some interests may not be considered a confl ict in one research project and may be a confl ict in another research project. Generally, there must be a relation between the research project and the potential confl ict. For example, consulting fees of $25,000 received from a device company may not be a confl ict in a research study on a drug sponsored by a diff erent company, but would be considered a confl ict in a research study sponsored by the same device company that pays the researcher to consult or speak on its behalf.
Federal regulations provide some guidance regarding what may be considered a signifi cant confl ict of interest. However, FDA regulations (10) diff er from the PHS regulations (11), resulting in additional complications. Th e FDA regulations apply to investigational new drugs and devices, while the PHS regulations apply to federally funded research. It is possible for both regulations to apply to a research project that involves an investigational product and funding from PHS. Th e FDA (12) and PHS (13) require disclosure of fi nancial interests by research personnel as well as their spouses and dependent children. Both sets of regulations provide monetary thresholds for what is considered a signifi cant confl ict (Table) .
REPORTING POTENTIAL CONFLICTS OF INTEREST
Transparency is touted as the key to mitigating confl icts and preserving reputable research. Transparency requires public disclosure of any and all private fi nancial arrangements and other interests that are directly or indirectly related to professional responsibilities. Public disclosure of any and all interests related to a research project is believed to allow research participants to become more informed and medical research as a whole to be more transparent. When a researcher is uncertain regarding the relation of an interest to a research project, disclosure is always the correct action.
At Baylor Health Care System, the research confl ict of interest process begins with disclosure. Disclosure of interests that may be related to research activity is essential to achieving transparency. Th e disclosure occurs at three points during the research project. Th e fi rst disclosure is made at the initial submission of a research project to the institutional review board (IRB) or when the funding application is submitted. Next, disclosures are made at each IRB periodic review of the project or annually. Finally, it is the obligation of all research personnel to provide an updated disclosure when a previously unreported activity arises or a signifi cant change occurs in previously reported activities. Th is obligation continues throughout the research project and for 1 year following completion of the project for FDA-regulated research (14) . Currently, PHS-funded research requires reporting of funds that would be expected to exceed the thresholds over the next 12 months (15).
MANAGING AND RESOLVING RESEARCH CONFLICTS
Baylor Health Care System established the Research Confl ict of Interest Committee to review fi nancial disclosure statements from all research personnel. Th e committee consists of physicians and scientists appointed by the Baylor Research Institute president and administrative representatives as designated in Research Confl ict of Interest Committee policy. Th e committee meets monthly or as may otherwise be scheduled to address research-related confl ict issues. Members do not receive compensation for their participation on the committee.
Disclosure triggers the confl ict resolution process. In 2010, 318 new research protocols were initiated, and all research personnel involved submitted a confl ict of interest disclosure statement. Researchers on 573 continuing projects also submitted disclosures for evaluation. Disclosures with potential confl icts were reviewed by the committee.
Th e committee evaluates and acts on the information disclosed by the researchers in order to determine whether to manage or to eliminate real and perceived confl icts. Factors considered by the committee include the monetary value of a confl ict, the scope of the interest or relationship, the duration Minimum threshold of $10,000 and/or >5% ownership interest in any single entity Any ownership interest, stock options, or other financial interest whose value cannot be readily determined through reference to public prices or any equity interest in a publicly traded corporation >$50,000
Applicable time In the 12 months preceding the disclosure Over the next 12 months During the time the clinical investigator is carrying out the study and for 1 year following completion of the study of the interest or relationship, the likelihood of undue infl uence, and the seriousness of harm. By providing detailed information on the disclosure forms, the researchers assist the committee in making appropriate decisions. Committee actions may include requiring additional disclosure to research participants, patients, or even the public. Most scientifi c journals require disclosure of confl icts when publishing research results, and the committee may require this disclosure as well. Other restrictions may be established by the committee for participation in the research by the researcher with the confl ict, such as not personally providing informed consent, not personally analyzing the research data, or instituting monitoring by external sources.
Some solutions require actions before the research begins in order to mitigate the confl ict. Th ese actions may include modifying the research plan or restricting the confl icted researcher from participation in portions of the research where confl icted.
Th ese are only examples of resolutions the committee may utilize to manage real or perceived confl icts. Th ere are confl icts that will not allow for any method of mitigation. Divestiture of the confl ict or severance of the relationship creating the confl ict may be the only alternative to allow the research project to continue. Th e committee makes every eff ort to reach a resolution allowing continuation of research while avoiding opportunity for undue infl uence from any real or perceived confl icting interests, but there are instances when the research cannot continue due to the nature of the confl ict.
Th e committee presents its recommendations to the researcher with identifi ed confl icts in the form of a resolution for the researcher to accept and implement. Th e resolution from the committee is approved by the Baylor Research Institute IRB. IRB approval of the research project is not released until the resolution has been accepted by the researcher and all elements of the management plan have been implemented.
Baylor Health Care System Research Compliance conducts monitoring to ensure the implementation of the resolution. Monitoring is used to determine whether each aspect of the management plan has been followed. Failure to implement the management plan can result in suspension or termination of the research project, or other actions by the institution as appropriate.
Each situation presents unique circumstances for consideration and careful weighing of the potential harm and benefi ts of actions that may be taken to avoid confl icts. Th e committee makes its best determination based on the information disclosed. Extenuating circumstances may exist that could potentially override the committee's recommendation and therefore result in an appeal. Researchers may appeal the decision in writing and present additional information for review.
Confl icts of interest will always be present in the conduct of research. Both the tangible and intangible confl icts will always exist, and the types of confl ict are certainly becoming more complex. Developing new strategies to manage, reduce, or eliminate confl icts of interest will continue to be a challenge. By making the process transparent and by carefully addressing any potential confl icts, the trust of the public and integrity of scientifi c research can be preserved.
